Below is a brief note from CEO Keith McCullough on why we're adding Zimmer Biomet (ZBH) to the long side of Investing Ideas today:
|
There's always a bull market somewhere and we have plenty of Healthcare ideas to choose from like TDOC and MD (when they are on sale). Another name our independent Healthcare Research Team currently likes is Zimmer (ZBH). It’s down -1.5% on #decelerating volume today and signaling immediate-term TRADE oversold within a Bullish @Hedgeye TREND. Top-down summary of the idea from Tom Tobin’s team: “We believe the current valuation and consensus estimates do not reflect the potential for a turnaround under new management and resolution of self-inflicted manufacturing problems.” I do like turnarounds. Buy on red, KM |
